Xarelto Injury Lawyers
Riley & Jackson’s pharmaceutical legal team is representing individuals who have been injured as a result of the anti-coagulant (blood thinner) Xarelto. Xarelto is a novel anti-coagulant that works differently than some of the better known anti-coagulants such as Coumadin (Warfarin) and Heparin. The drug is manufactured by Bayer and is marketed in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Anti-coagulants have been used for decades. Because these drugs make the blood thinner, excessive bleeding is a risk associated with using these drugs. The traditional anti-coagulants have reversal agents, or antidotes. This means that a patient who has uncontrolled bleeding can receive a specific medication, and the bleeding will stop. Vitamin K rapidly stops excessive bleeding associated with Coumadin, and Protamine rapidly stops excessive bleeding associated with Heparin. Bayer manufactured Xarelto, and Janssen marketed it to physicians and patients, with knowledge that there is no antidote for Xarelto. If a patient using Xarelto begins bleeding excessively, that patient can bleed to death or suffer other catastrophic injuries because the bleeding cannot be stopped.
Xarelto also has an unusually low therapeutic index. This means the medication may be safe at a certain level but dangerous within a very close range of the safe level. Because Bayer intended Xarelto to be prescribed as a “one size fits all” medication, its low therapeutic index creates substantial risk. The drug can have dramatically different effects on patients depending on their individual characteristics, but Bayer and Janssen failed to account for this in their manufacturing and marketing of the drug and failed to disclose the risks to patients and physicians.
A number of significant injuries can occur as a result of using Xarelto. These injuries include, but are not limited to, the following:
- Death from excessive bleeding
- Intracranial hemorrhage, or bleeding within the skull
- Epidural hematoma, or bleeding in a specific part of the brain
- Gastrointestinal hemorrhage, also known as a GI bleed
- Hemorrhagic stroke
- Surgical site infections
- Retinal hemorrhage, or bleeding on the back wall of the eye
- Adrenal hemorrhage
Bayer and Janssen marketed Xarelto for use in patients with atrial fibrillation not caused by a heart valve problem to reduce the risk of stroke, for the prevention of deep vein thrombosis and pulmonary embolism, and for the prevention of blood clots following hip or knee replacement surgery. Bayer and Janssen also heavily touted that patients do not need regular blood level checks while taking Xarelto but failed to disclose the fact that no antidote or reversal agent would be available if the patient suffered excessive bleeding.
If you or a loved one took Xarelto and suffered any of the injuries listed above, please contact the attorneys at Riley & Jackson to discuss whether you may have a claim for financial compensation.